These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31272795)

  • 1. Discovery and pharmacological evaluation of indole derivatives as potent and selective RORγt inverse agonist for multiple autoimmune conditions.
    Shaikh NS; Iyer JP; Munot YS; Mukhopadhyay PP; Raje AA; Nagaraj R; Jamdar V; Gavhane R; Lohote M; Sherkar P; Bala M; Petla R; Meru A; Umrani D; Rouduri S; Joshi S; Reddy S; Kandikere V; Bhuniya D; Kulkarni B; Mookhtiar KA
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2208-2217. PubMed ID: 31272795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization and biological evaluation of thiazole-bis-amide inverse agonists of RORγt.
    Gege C; Albers M; Kinzel O; Kleymann G; Schlüter T; Steeneck C; Hoffmann T; Xue X; Cummings MD; Spurlino J; Milligan C; Fourie AM; Edwards JP; Leonard K; Coe K; Scott B; Pippel D; Goldberg SD
    Bioorg Med Chem Lett; 2020 Jun; 30(12):127205. PubMed ID: 32336498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of N-(2-benzyl-4-oxochroman-7-yl)-2-(5-(ethylsulfonyl) pyridin-2-yl) acetamide (b12) as a potent, selective, and orally available novel retinoic acid receptor-related orphan receptor γt inverse agonist.
    Chen L; Su M; Jin Q; Wang CG; Assani I; Wang MX; Zhao SF; Lv SM; Wang JW; Sun B; Li Y; Liao ZX
    Bioorg Chem; 2022 Feb; 119():105483. PubMed ID: 34906860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of aryl-substituted indole and indoline derivatives as RORγt agonists.
    Zhu Y; Sun N; Yu M; Guo H; Xie Q; Wang Y
    Eur J Med Chem; 2019 Nov; 182():111589. PubMed ID: 31425906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of carboxyl-containing biaryl ureas as potent RORγt inverse agonists.
    Sun N; Huang Y; Yu M; Zhao Y; Chen JA; Zhu C; Song M; Guo H; Xie Q; Wang Y
    Eur J Med Chem; 2020 Sep; 202():112536. PubMed ID: 32698100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel triazine derivatives as potent retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists.
    Lu L; Chen S; Yu M; Zhou R; Guo S; Chen JA; Wang H; Chen S; Luo C; Xie Q; Wang Y
    Eur J Med Chem; 2023 Aug; 256():115424. PubMed ID: 37167779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Inverse) Agonists of Retinoic Acid-Related Orphan Receptor γ: Regulation of Immune Responses, Inflammation, and Autoimmune Disease.
    Jetten AM; Cook DN
    Annu Rev Pharmacol Toxicol; 2020 Jan; 60():371-390. PubMed ID: 31386594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 1-{4-[3-fluoro-4-((3s,6r)-3-methyl-1,1-dioxo-6-phenyl-[1,2]thiazinan-2-ylmethyl)-phenyl]-piperazin-1-yl}-ethanone (GNE-3500): a potent, selective, and orally bioavailable retinoic acid receptor-related orphan receptor C (RORc or RORγ) inverse agonist.
    Fauber BP; René O; Deng Y; DeVoss J; Eidenschenk C; Everett C; Ganguli A; Gobbi A; Hawkins J; Johnson AR; La H; Lesch J; Lockey P; Norman M; Ouyang W; Summerhill S; Wong H
    J Med Chem; 2015 Jul; 58(13):5308-22. PubMed ID: 26061388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of potent, selective and orally bioavailable phenyl ((R)-3-phenylpyrrolidin-3-yl)sulfone analogues as RORγt inverse agonists.
    Lu Z; Duan JJ; Xiao H; Neels J; Wu DR; Weigelt CA; Sack JS; Khan J; Ruzanov M; An Y; Yarde M; Karmakar A; Vishwakrishnan S; Baratam V; Shankarappa H; Vanteru S; Babu V; Basha M; Kumar Gupta A; Kumaravel S; Mathur A; Zhao Q; Salter-Cid LM; Carter PH; Murali Dhar TG
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2265-2269. PubMed ID: 31257087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of N-indanyl benzamides as potent RORγt inverse agonists.
    Tian J; Sun N; Yu M; Gu X; Xie Q; Shao L; Liu J; Liu L; Wang Y
    Eur J Med Chem; 2019 Apr; 167():37-48. PubMed ID: 30743096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 2-(Ortho-Substituted Benzyl)-Indole Derivatives as Potent and Orally Bioavailable RORγ Agonists with Antitumor Activity.
    Lu B; Liu D; Gui B; Gou J; Dong H; Hu Q; Feng J; Mao Y; Shen X; Wang S; Zhang C; Shen R; Yan Y; Chen L; Wang H; Li D; Zhang J; Zhang M; Zhang R; Bai C; He F; Tao W; Liu S
    J Med Chem; 2021 Oct; 64(20):14983-14996. PubMed ID: 34643383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of [ cis-3-({(5 R)-5-[(7-Fluoro-1,1-dimethyl-2,3-dihydro-1 H-inden-5-yl)carbamoyl]-2-methoxy-7,8-dihydro-1,6-naphthyridin-6(5 H)-yl}carbonyl)cyclobutyl]acetic Acid (TAK-828F) as a Potent, Selective, and Orally Available Novel Retinoic Acid Receptor-Related Orphan Receptor γt Inverse Agonist.
    Kono M; Ochida A; Oda T; Imada T; Banno Y; Taya N; Masada S; Kawamoto T; Yonemori K; Nara Y; Fukase Y; Yukawa T; Tokuhara H; Skene R; Sang BC; Hoffman ID; Snell GP; Uga K; Shibata A; Igaki K; Nakamura Y; Nakagawa H; Tsuchimori N; Yamasaki M; Shirai J; Yamamoto S
    J Med Chem; 2018 Apr; 61(7):2973-2988. PubMed ID: 29510038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of imidazo[1,5-a]pyridines and -pyrimidines as potent and selective RORc inverse agonists.
    Fauber BP; Gobbi A; Robarge K; Zhou A; Barnard A; Cao J; Deng Y; Eidenschenk C; Everett C; Ganguli A; Hawkins J; Johnson AR; La H; Norman M; Salmon G; Summerhill S; Ouyang W; Tang W; Wong H
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2907-12. PubMed ID: 26048793
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and structural optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1H)-ones as RORc inverse agonists.
    Wu XS; Wang R; Xing YL; Xue XQ; Zhang Y; Lu YZ; Song Y; Luo XY; Wu C; Zhou YL; Jiang JQ; Xu Y
    Acta Pharmacol Sin; 2016 Nov; 37(11):1516-1524. PubMed ID: 27374490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of orally efficacious RORγt inverse agonists. Part 2: Design, synthesis, and biological evaluation of novel tetrahydroisoquinoline derivatives.
    Kono M; Oda T; Tawada M; Imada T; Banno Y; Taya N; Kawamoto T; Tokuhara H; Tomata Y; Ishii N; Ochida A; Fukase Y; Yukawa T; Fukumoto S; Watanabe H; Uga K; Shibata A; Nakagawa H; Shirasaki M; Fujitani Y; Yamasaki M; Shirai J; Yamamoto S
    Bioorg Med Chem; 2018 Jan; 26(2):470-482. PubMed ID: 29258712
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of novel N-sulfonamide-tetrahydroquinolines as potent retinoic acid receptor-related orphan receptor γt inverse agonists for the treatment of autoimmune diseases.
    Sun N; Ma X; Zhou K; Zhu C; Cao Z; Wang Y; Xu J; Fu W
    Eur J Med Chem; 2020 Feb; 187():111984. PubMed ID: 31881455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of Interleukin-23-Mediated Inflammation with a Novel Small Molecule Inverse Agonist of ROR
    Gauld SB; Jacquet S; Gauvin D; Wallace C; Wang Y; McCarthy R; Goess C; Leys L; Huang S; Su Z; Edelmayer R; Wetter J; Salte K; McGaraughty SP; Argiriadi MA; Honore P; Luccarini JM; Bressac D; Desino K; Breinlinger E; Cusack K; Potin D; Kort ME; Masson PJ
    J Pharmacol Exp Ther; 2019 Oct; 371(1):208-218. PubMed ID: 31375639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of orally efficacious RORγt inverse agonists, part 1: Identification of novel phenylglycinamides as lead scaffolds.
    Shirai J; Tomata Y; Kono M; Ochida A; Fukase Y; Sato A; Masada S; Kawamoto T; Yonemori K; Koyama R; Nakagawa H; Nakayama M; Uga K; Shibata A; Koga K; Okui T; Shirasaki M; Skene R; Sang B; Hoffman I; Lane W; Fujitani Y; Yamasaki M; Yamamoto S
    Bioorg Med Chem; 2018 Jan; 26(2):483-500. PubMed ID: 29262987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel pyrazole-containing benzamides as potent RORγ inverse agonists.
    Wang T; Banerjee D; Bohnert T; Chao J; Enyedy I; Fontenot J; Guertin K; Jones H; Lin EY; Marcotte D; Talreja T; Van Vloten K
    Bioorg Med Chem Lett; 2015 Aug; 25(15):2985-90. PubMed ID: 26048789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibitory profile of TAK-828F, a potent and selective orally available RORγt inverse agonist.
    Shibata A; Uga K; Sato T; Sagara M; Igaki K; Nakamura Y; Ochida A; Kono M; Shirai J; Yamamoto S; Yamasaki M; Tsuchimori N
    Biochem Pharmacol; 2018 Apr; 150():35-45. PubMed ID: 29369782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.